Drug Database
Back to search

Poland· PL-100313894

Vipdomet

A metformin and alogliptin product containing metformini hydrochloridum + alogliptinum, registered in Poland by Takeda Pharma A/S. The same ATC class is registered in 10 of our 19 countries.

ATC A10BD13

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedVipdometATCA10BD13REGISTER NO.PL-100313894PACKS LISTED0CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about metformini hydrochloridum + alogliptinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Metformin and alogliptin is registered in 10 of 19 countries.

Countries holding a registration under ATC A10BD13 (metformin and alogliptin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 5 of them publish a price we can compare per daily dose
Search metformin and alogliptin products by name

Metformin and alogliptin · ATC A10BD13

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Metformini hydrochloridum + Alogliptinum
Manufacturer
Takeda Pharma A/S
Country
Poland (PL)
ATC code
A10BD13
ATC class
Metformin and alogliptin
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

3 interactions on record for metformin and alogliptin.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check metformin and alogliptin against other medicinesHow interaction checks work

Metformin and alogliptin · interactions on record

3 records

3 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Metformin and alogliptin in 6 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All metformin and alogliptin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Vipdomet
  • Liechtenstein · Vipdomet
  • Norway · Vipdomet

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4f0fab0b-8672-4bbc-a796-9630ce658e69
GET /v1/drugs/4f0fab0b-8672-4bbc-a796-9630ce658e69?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "850 mg + 12,5 mg",
  "packaging": "Rp ¦ EU/1/13/843/001 ¦ 90592\n10 tabl.\nRp ¦ EU/1/13/843/002 ¦ 90593\n14 tabl.\nRp ¦ EU/1/13/843/003 ¦ 90594\n20 tabl.\nRp ¦ EU/1/13/843/004 ¦ 90595\n28 tabl.\nRp ¦ EU/1/13/843/005 ¦ 90596\n56 tabl.\nRp ¦ EU/1/13/843/006 ¦ 90597\n60 tabl.\nRp ¦ EU/1/13/843/007 ¦ 90598\n98 tabl.\nRp ¦ EU/1/13/843/008 ¦ 90599\n112 tabl.\nRp ¦ EU/1/13/843/009 ¦ 90600\n120 tabl.\nRp ¦ EU/1/13/843/010 ¦ 90601\n180 tabl.\nRp ¦ EU/1/13/843/011 ¦ 90602\n196 tabl.\nRp ¦ EU/1/13/843/012 ¦ 90603\n200 tabl.\nRp ¦ EU/1/13/843/025 ¦ 122316\n196 tabl. (2 x 98)",
  "substance": "Metformini hydrochloridum 850 mg + Alogliptinum 12.5 mg",
  "common_name": "Metformini hydrochloridum + Alogliptinum",
  "pl_product_id": "100313894",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about metformin and alogliptin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console